Galatea Bio
Venture Round in 2025
Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.
Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.
Zafrens is a drug discovery company based in San Diego, California, founded in 2021. The company specializes in developing life sciences products that facilitate the comprehensive characterization of diverse cell populations. Its innovative platform focuses on generating insights at the intersection of biology, chemistry, and engineering. Zafrens employs a resolution approach to study interactions between cells and drugs by directly mapping the molecular states of individual cells. The extensive volume of curated experimental data generated by Zafrens is utilized to train artificial intelligence models aimed at advancing drug discovery. Additionally, the company possesses internal expertise in T cell immunotherapies and ribonucleic acid regulation, leveraging its proprietary data and experimental capabilities to support advancements in the medical industry.
Chemify is a developer of a chemical digitization platform that integrates automated synthetic hardware with a unique chemical programming language. This platform allows for the on-demand conversion of digital code into molecules, facilitating drug and materials discovery as well as chemical synthesis. Chemify's system is designed to be modular, universal, scalable, and teachable, making it suitable for various applications in chemical and material research. The software incorporates natural language processing to translate synthetic procedures and features a comprehensive ontology, which aids users in creating chemical processes while providing insights into reaction conditions and identifying potential issues. This capability enables scientists to access detailed real-time telemetry of chemical reactions, enhancing efficiency and accuracy in their work.
Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.
Zafrens
Seed Round in 2021
Zafrens is a drug discovery company based in San Diego, California, founded in 2021. The company specializes in developing life sciences products that facilitate the comprehensive characterization of diverse cell populations. Its innovative platform focuses on generating insights at the intersection of biology, chemistry, and engineering. Zafrens employs a resolution approach to study interactions between cells and drugs by directly mapping the molecular states of individual cells. The extensive volume of curated experimental data generated by Zafrens is utilized to train artificial intelligence models aimed at advancing drug discovery. Additionally, the company possesses internal expertise in T cell immunotherapies and ribonucleic acid regulation, leveraging its proprietary data and experimental capabilities to support advancements in the medical industry.
Pair Team
Seed Round in 2021
Pair Team focuses on enhancing primary care infrastructure for vulnerable communities, particularly those served by safety-net systems, Medicaid, and Medicare patients. As a tech-enabled care team, it extends the capabilities of clinical staff by offering personalized, high-touch care experiences. The organization addresses various barriers to healthcare, including transportation issues, housing and food insecurity, and limited mobile access. Pair Team employs a dedicated care team consisting of community health workers, registered nurses, and behavioral health clinicians to deliver comprehensive support tailored to the needs of low-income individuals. Additionally, the company is developing a care delivery platform designed to implement clinical best practices, integrate services with community-based organizations, and streamline administrative tasks, allowing clinicians to dedicate more time to patient care.
Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.
Zafrens
Pre Seed Round in 2021
Zafrens is a drug discovery company based in San Diego, California, founded in 2021. The company specializes in developing life sciences products that facilitate the comprehensive characterization of diverse cell populations. Its innovative platform focuses on generating insights at the intersection of biology, chemistry, and engineering. Zafrens employs a resolution approach to study interactions between cells and drugs by directly mapping the molecular states of individual cells. The extensive volume of curated experimental data generated by Zafrens is utilized to train artificial intelligence models aimed at advancing drug discovery. Additionally, the company possesses internal expertise in T cell immunotherapies and ribonucleic acid regulation, leveraging its proprietary data and experimental capabilities to support advancements in the medical industry.
Teiko.bio
Venture Round in 2021
Teiko.bio is an immune profiling platform founded in 2020 and based in Salt Lake City, Utah. The company focuses on delivering insights that assist clinicians in making informed decisions regarding patient responses to therapies. Its platform analyzes immune features linked to treatment responses, identifies rational targets for potential combination therapies, and evaluates the abundance and activation levels of various immune cell types. By providing this comprehensive immune profiling, Teiko.bio aims to enhance patient outcomes and facilitate new discoveries in therapeutic pathways.
Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.
Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.
Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.
Circularis Biotechnologies
Seed Round in 2020
Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.
Pair Team
Seed Round in 2019
Pair Team focuses on enhancing primary care infrastructure for vulnerable communities, particularly those served by safety-net systems, Medicaid, and Medicare patients. As a tech-enabled care team, it extends the capabilities of clinical staff by offering personalized, high-touch care experiences. The organization addresses various barriers to healthcare, including transportation issues, housing and food insecurity, and limited mobile access. Pair Team employs a dedicated care team consisting of community health workers, registered nurses, and behavioral health clinicians to deliver comprehensive support tailored to the needs of low-income individuals. Additionally, the company is developing a care delivery platform designed to implement clinical best practices, integrate services with community-based organizations, and streamline administrative tasks, allowing clinicians to dedicate more time to patient care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.